Pataday Related Published Studies
Well-designed clinical trials related to Pataday (Olopatadine Ophthalmic)
Efficacy of oral olopatadine hydrochloride for the treatment of seasonal allergic
rhinitis: A randomized, double-blind, placebo-controlled study. [2010]
Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. [2009.08]
Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. [2008.07.08]
Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye. [2008.02]
Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge. [2007.12]
Safety and tolerability of olopatadine 0.2% in children and adolescents. [2007.08]
Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis. [2007.07]
Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge. [2007.06]
Efficacy and response with olopatadine versus epinastine in ocular allergic symptoms: a post hoc analysis of data from a conjunctival allergen challenge study. [2006.10]
Improved quality of life among seasonal allergic rhinitis patients treated with olopatadine HCl nasal spray 0.4% and olopatadine HCl nasal spray 0.6% compared with vehicle placebo. [2006.05]
Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy. [2005.10]
Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial. [2005.09]
A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model. [2005.05]
Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis. [2005.05]
Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model. [2004.12]
Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study. [2004.08]
Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model. [2004.08]
Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration. [2004.01]
Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans. [2003.10]
Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models. [2003.08]
Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. [2003.08]
One-visit, randomized, placebo-controlled, conjunctival allergen challenge study of scanning and imaging technology for objective quantification of eyelid swelling in the allergic reaction with contralateral use of olopatadine and artificial tears. [2003.07]
Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge model. [2003.04]
A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis. [2003.03]
Ketotifen fumarate and olopatadine hydrochloride in the treatment of allergic conjunctivitis: a real-world comparison of efficacy and ocular comfort. [2003.03]
A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis. [2002.10]
Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge. [2002.07]
Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model. [2002.06]
Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. [2001.08]
Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms. [2001.06]
Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model. [2000.12]
A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model. [2000.07]
A forced choice comfort study of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%. [2000]
An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model. [2000]
Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model. [1999]
Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. [1998.09]
Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. [1998.06]
Well-designed clinical trials possibly related to Pataday (Olopatadine Ophthalmic)
Treatment of allergic conjunctivitis: results of a 1-month, single-masked randomized study. [2010.09]
[Comparison of olopatadin and ketotifen in the treatment of allergic conjunctivitis] [2009.07]
The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model. [1999]
Other research related to Pataday (Olopatadine Ophthalmic)
Comparative evaluation of olopatadine 0.01% combined fluorometholone 0.1%
treatment versus olopatadine 0.01% combined ketorolac 0.4% treatment in patients
with acute seasonal allergic conjunctivitis. [2014]
Effect of intranasal fluticasone furoate and intraocular olopatadine on nasal and
ocular allergen-induced symptoms. [2013]
Pre-seasonal treatment with topical olopatadine suppresses the clinical symptoms of seasonal allergic conjunctivitis. [2011.04]
Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis. [2011.02.08]
Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%. [2011.01.13]
Efficacy of oral olopatadine hydrochloride for the treatment of seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled study. [2010.07]
Comparison of olopatadine and fluorometholone in contact lens-induced papillary conjunctivitis. [2010.07]
Olopatadine: a drug for allergic conjunctivitis targeting the mast cell. [2010.04]
Comprehensive review of olopatadine: the molecule and its clinical entities. [2010.03]
Comparison of olopatadine and fluorometholone in contact lens-induced papillary
conjunctivitis. [2010]
[Effectiveness of olopatadine therapy in seasonal allergic conjunctivitis] [2009]
Use of olopatadine ophthalmic solution and reactivity of histamine skin testing. [2008.11]
A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis. [2008.11]
Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing. [2008.04]
Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitis. [2007.11]
Effects of topical anti-inflammatory agents in a botulinum toxin B-induced mouse model of keratoconjunctivitis sicca. [2007.02]
Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice. [2006.12]
[Comparative study between 0.025% ketotifen fumarate and 0.1% olopatadine hydrochloride in the treatment of vernal keratoconjunctivitis.] [2006.11]
[First Hungarian report of olopatadine eyedrop therapy in children and adults suffering from seasonal allergic conjunctivitis] [2006.09.10]
Allergic tears promote upregulation of eosinophil adhesion to conjunctival epithelial cells in an ex vivo model: inhibition with olopatadine treatment. [2006.08]
Other possibly related research studies
Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo. [2007.11]
Duration of action of topical antiallergy drugs in a Guinea pig model of histamine-induced conjunctival vascular permeability. [2007.08]
Alcaligenes xylosoxidans conjunctivitis. [2007.08]
Comparative efficacy of topical antihistamines in an animal model of early phase allergic conjunctivitis. [2008.05]
Comparison of the conjunctival toxicity of topical ocular antiallergic agents. [2008.12]
Multiple action agents and the eye: do they really stabilize mast cells? [2009.10]
Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model. [2009.07.28]
Intrastromal corneal ring segments for bilateral keratoconus in an 11-year-old boy. [2011.01]
Alcaftadine: a topical antihistamine for use in allergic conjunctivitis. [2011]
Treatment of allergic conjunctivitis: results of a 1-month, single-masked
randomized study. [2010]
Efficacy of epinastine hydrochloride ophthalmic solution in allergic
conjunctivitis by conjunctival cedar pollen allergen challenge. [2014]
|